In The News: December 2013

The Food and Drug Administration (FDA) has approved ustekinumab (Stelara), alone or in combination with methotrexate, for the treatment of adult patients (18 years of age or older) with active psoriatic arthritis. Administered as a 45-mg subcutaneous (SC) injection, ustekinumab is given at weeks zero and four, and then every 12 weeks thereafter.
To continue reading this article or issue you must be a paid subscriber. Sign in

Subscribe to Arthritis Advisor

Get the next year of Arthritis Advisor for just $20. And access all of our online content - over 1,000 articles - free of charge.
Subscribe today and save 36%. It's like getting 4 months FREE!
Already Subscribed?
Click Here to Sign In | Forgot your password? | Activate Web Access